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Basic research using animal models points to a causal role of the central nervous system in essential hypertension; however, since
clinical research is technically diﬃcult to perform, this connection has not been conﬁrmed in humans. Recently, renal nerve
ablation in humans proved to continuously decrease blood pressure in resistant hypertension. Furthermore, when electrical
stimulation was continuously applied to the carotid baroreceptor nerve of human adults, their blood pressure lowered. These
ﬁndings promoted the concept that the central nervous system may actually be involved in the pathogenesis of essential
hypertension, which is closely associated with excess sodium intake. We have demonstrated that endogenous digitalis plays a key
role in hypertension associated with excess sodium intake via sympathetic activation in rats. Increased sodium concentration
inside the brain activates epithelial sodium channels and the renin-angiotensin-aldosterone system in the brain. Aldosterone
releases ouabain from neurons in the paraventricular nucleus in the hypothalamus. Angiotensin II and aldosterone of peripheral
origin reach the brain to augment sympathetic outﬂow. Collectively essential hypertension associated with excess sodium intake
and obesity, renovascular hypertension, and primary aldosteronism and pseudoaldosteronism all seem to have a common cause
originating from the central nervous system.
1.Introduction
Bloodpressure(BP)isaphysiologicalphenomenonlikebody
temperature, respiration, and pulse rate; its dysregulation
most often results in hypertension. BP regulation is operated
via sympathetic and parasympathetic nerves, as well as the
release of pituitary hormones. However, antihypertensive
agents such as diuretics, beta blockers, alpha blockers, cal-
cium channel blockers (CCBs), mineralocorticoid receptor
blockers (MRBs), and antagonists for the renin-angiotensin
system (RAS) eﬀectively lower the BP, and their sites action
lie in the peripheral tissues. These antihypertensive treat-
ments seem to have little or no connection with the central
nervous system (CNS) regulation of BP; thus, if a central
mechanism does exist, its actual regulatory role is believed to
be minimal, and, therefore, any such central mechanism of
hypertension has not been investigated extensively. However,
evidence from animal models has demonstrated the role of
sympathetic nervous system activity (SNSA) in hypertension
[1–3].Forexample,renaldenervationconsistentlylowersthe
BP in a variety of animal models of hypertension [4–6]. In
line with this, renal denervation by catheter-based radiofre-
quency ablation technology has been shown to eﬀectively
lower BP in patients with resistant hypertension at least for
2y e a r s[ 7]. As Guyton’s model [8] predicted that the renal
function to excrete sodium is the inﬁnite determinant of
hypertension,denervationnatriuresismaybethemechanism
ofactionofrenaldenervation,demonstratingthecrucialrole
of peripheral SNSA. Furthermore, interventional activation
ofthecarotidbaroreﬂexviacontinuouselectricalstimulation
with an implantable device has been shown to eﬀectively
lower BP by decreasing SNSA in patients with resistant
hypertension [9]. This evidence indicates that the central
setting level of BP regulation is elevated at the higher level2 International Journal of Hypertension
in hypertensive patients. These 2 important observations led
ustoconsidertheroleofSNSAinthegenesisofhypertension
in humans.
In addition to these ﬁndings, other evidence to conﬁrm
the role of CNS in the genesis of hypertension has been
revealed:asmalldoseofangiotensinII(Ang II)continuously
administered subcutaneously (SC) gradually elevates BP,
which can be abolished by intracerebroventricular (ICV)
pretreatment with either an aldosterone synthase inhibitor
or an MRB in rats [10]. Similar ﬁndings have been demon-
strated with aldosterone: SC administration of aldosterone
with 1% NaCl saline, as drinking water in rats gradually
elevates BP, which is blunted by ICV pretreatment with
either an Ang II AT-1 receptor blocker (ARB) or MRB [11].
These observations indicate that secondary hypertension
such as primary aldosteronism, pseudoaldosteronism, and
renovascular hypertension should be classiﬁed as centrally
induced hypertension. Furthermore, central abolition of
BP increases with ARB or MRB treatment, indicating that
the major classes of antihypertensive agents may primarily
be acting at a central site to lower BP. In fact, reﬂex
tachycardia is absent when treated with the abovementioned
antihypertensive agents, indicating that these agents lower
BP by acting at a central site to set the BP to a lower level.
In this paper, these are the particular points of discussion.
2. ArterialHypertensionandSNSA
The role of the autonomic nervous system activity in
the pathogenesis of essential hypertension has been exten-
sively studied [12–14]. Measurement of urinary excretion
of norepinephrine has shown increased SNSA in animal
models of hypertension, such as spontaneously hyperten-
sive rats [15], Dahl salt sensitive rats [16], and models
of deoxycorticosterone acetate (DOCA)-salt hypertension
[17], Goldblatt renovascular hypertension [18], and renal
mass-reduced hypertension [19]. Furthermore, there are
numerous reports showing elevated urinary excretion of
catecholamines in humans [20]; however, the diﬀerence
between normal controls and hypertensive subjects is not
high enough to establish the role of SNSA in hypertension.
On the other hand, SNSA is notably elevated in young
subjects with labile hypertension who are believed to be in
an early phase of essential hypertension [21]. SNSA is clearly
increased among obese subjects with metabolic syndrome
who are prone to be hypertensive and is decreased with a
signiﬁcant reduction in body weight [22, 23]. Augmented
SNSA may be due to increased leptin, which is secreted from
fat cells and stimulates SNSA via actions on the arcuate
nucleus in the hypothalamus, and suppresses appetite [24].
When rats are fed a high-fat diet, they become resistant
to appetite suppression but not resistant to sympathetic
activation leading to hypertension [25]. However, SNSA is
not much augmented in those hypertensive animals and
humans, rather it is nearly normal due to suppression by the
BP elevation caused by the initial increase in SNSA; that is,
the SNSA converges to a near-normal level after a certain
level of increase in the BP caused by an initial increase in
SNSA. The subtle elevation of SNSA will be maintaining the
elevated BP.
3. Sodium, SNSA, andHypertension
Our ancestors living inland during the Stone Age would have
consumed natural foods like wild animals do, and sodium
intakewouldhavebeensuitableattheminimumforsurvival.
Epidemiological surveys of Yanomamo Indians in Amazon,
Brazil, who, until recently, had been living like the people
in the Stone Age did, revealed that their urinary excretion
of sodium was only 0.9mmol/day (equivalent to 0.53g of
sodium chloride) [26]. This is roughly 1/20th of the average
sodium intake in modern societies, and this small amount
of sodium was proven to be suﬃcient to live. In fact, all
vertebrates, except human beings and domestic animals,
consume only natural food without adding sodium salt. The
average BP of the Yanomamo Indians was 96.0/60.6mmHg,
and the level did not elevate depending on age, which
is in contrast to the observation in modern populations.
The average life span of people who lived in the Stone
Age is thought to be approximately 30 years, which is too
low to cause atherosclerotic vascular complications, even if
hypertension existed. Rather, higher BP would be better to
supply enough blood to the principal organs and skeletal
muscles. Renovascular hypertension may be a good example:
when renal blood supply is impaired due to narrowing of
renalarteries, theRASisactivatedtoraisetheBPtomaintain
suﬃcient blood supply to the kidney. Thus, hypertension
might have been a beneﬁt for people in the Stone Age who
wereoftenattackedbyenemiesandwildanimals;peoplewho
had a prompt elevation in BP could survive and leave oﬀ-
spring.TomaintainahighBP,largeamountofsodiumwould
be needed, and thus, salt-sensitive subjects would be selected
to survive. Those whose bodies promptly elevated the BP
uponexposuretostresscouldsucceedingenealogicalhistory.
Therefore, their oﬀspring are the people living now, and we
are salt-sensitive and prone to hypertension. Mechanisms
to retain as much sodium as possible were required, the
most powerful of which is the renin-angiotensin-aldosterone
system (RAAS) [27]. In subjects who consume low amounts
of sodium, the RAAS is working at full strength, as is the case
for patients with Bartter syndrome. In addition, increased
sympathetic outﬂow accelerates sodium reabsorption from
the renal tubules via renal nerves [28]. Similarly, insulin
acts to retain sodium available at renal tubules; this action
is exaggerated in the early stage of diabetes mellitus and
metabolic syndrome associated with obesity. The precise
mechanism of how insulin retains sodium at the renal
tubules is now well known.
Together, strong sodium-retaining mechanisms were a
desirable trait and selected in later generations. Therefore,
hypertension easily develops after excess intake of sodium.
This trait was selected to correct our life style with a
lower intake of sodium; as a result, the incidence of stroke
is markedly decreased in Japan [29]. Understanding the
mechanism of induction of hypertension after excess intake
of sodium will help to devise eﬃcient measures to controlInternational Journal of Hypertension 3
the BP even after excessive sodium intake. A recent approach
to elucidate these mechanisms revealed that the brain RAAS
and endogenous digitalis are essentially involved in the
induction of hypertension.
4. Endogenous Digitalisunderlies the
Connection of Sodiumand Hypertension
Continuous administration of mineralocorticoids causes
sodium accumulation, which results in natriuresis at a
certain point, described as an escape phenomenon [30].
Factors associated with natriuresis include the glomerular
ﬁltration rate of the kidney, aldosterone, and other factors.
The others are referred to as third factors [31] .S i n c ei ti sw e l l
known that endogenous digitalis, an inhibitor for Na+/K+-
ATPase, circulates and that the activity of tissue Na+/K+-
ATPase decreases during sodium loading [32], endogenous
digitalis is the most probable candidate for a third factor.
Digoxin has been used for treating patients with congestive
heart failure or tachyarrhythmias. Because it may cause
intoxication, serum digoxin-like immunoreactivity (DLI)
levels have been monitored, and signiﬁcant levels of DLI
have been detected in subjects not consuming digitalis
glycosides [33]; this suggests the presence of endogenous
digoxin. In fact, digoxin has been detected in human plasma
by liquid chromatography and mass spectrometry [34].
Further, the turnover ratio of DLI in the hypothalamus and
its plasma concentration increase with increasing sodium
loading [35]. This suggests that digoxin may be produced
in the hypothalamus and released into circulation. In fact,
increased DLI concentrations were detected in the plasma
of DOCA-salt hypertensive rats [36]. In humans, urinary
excretion of DLI was found to be correlated with urinary
excretions of sodium or BP during a medical checkup [33].
However, the DLI concentrations were not high enough to
completely explain the pressor mechanism.
Ouabain, another water-soluble cardenolide, is known
to be of endogenous origin [37]. Administration of low-
dose ouabain causes sustained elevation of BP [38]. The
Milan hypertensive rat model is known to have a mutation
coding adducin, which augments the renal Na+/K+-ATPase
to increase sodium accumulation and hypertension [39]. In
this model, plasma ouabain levels are increased. PST2238,
or rostafuroxin, is an analogue of digitoxygenin, and it
antagonizes the action of ouabain and decreases BP in Milan
hypertensive rats [40]. Since hypertension induced by low-
dose ouabain is abolished by rostaﬂoxin [41], ouabain must
be directly involved in causing hypertension. Like Milan
hypertensive rats, humans with adducin polymorphisms
haveelevatedcirculatingouabainlevels,androstafuroxinwas
found to be eﬀective in lowering their BP [42]. However,
results of a large-scale clinical study did not conclusively
prove this [43].
Immunohistochemical approach using anti-ouabain or
anti-digoxin antibody revealed that neurons in the par-
aventricular nucleus (PVN) and supraoptic nucleus (SON)
showed ouabain- or digoxin-like immunoreactivity (OLI or
DLI) [44–46]. Both OLI and DLI are detected not only in
neuronal cell bodies but also in their dendrites and vari-
cosities, which resembles the distribution of neuroendocrine
hormones. The nerve ﬁbers densely extend to the median
eminence, subfornical organ (SFO), and organum vascu-
losum of the laminae terminalis (OVLT). Sodium loading
increased the turnover ratio of DLI in the hypothalamus
[35], and destruction of microtubules by ICV injection
of colchicine increased DLI in the hypothalamus [35].
Therefore, DLI is clearly produced in the hypothalamus,
PVN, and SON, which are stimulated by sodium loading.
Although we did not explore similar experiments concerning
the OLI, similar results are expected.
Since a low dose of ouabain injected into the lateral
ventricle or the hypothalamus of rats increases the BP along
with increasing the peripheral SNSA [47, 48], it seems likely
thattherearereceptorsforouabainandendogenousouabain
acts as a neurotransmitter to increase SNSA.
Immortalized N1 cells are thought to be of PVN origin
because these cells release vasopressin and oxytocin when
stimulated [49]. Experiments on N1 cell line cultured in a
serum-freeconditionshowedthatouabainwasreleasedfrom
these cells in a time-dependent manner; therefore, ouabain
must be produced in the hypothalamus.
5.BrainRAAS andSodiumMetabolism
(Figure1)
Inaclinicalsetting,BPinessentialhypertensioncanbeeasily
controlled with excellent antihypertensive agents such as
diuretics, CCBs, angiotensin I converting enzyme inhibitors
(ACEIs), ARBs, and MRBs. Sites where these agents act
are crucial for BP regulation. In particular, ACEIs and
ARBs are very eﬀective in controlling BP and preventing
complications, which indicates that RAAS is essential to
the pathogenesis of hypertension. These drugs are eﬀective
in high-renin patients but still serve to lower BP even
in those with low plasma renin activity (PRA) [50]. The
RAAS has not been considered to be involved in sodium-
sensitive hypertension because PRA is suppressed with
sodium loading. On the other hand, in addition to the
renal-reninandadrenalaldosteronesystem,RAASwasfound
to exist in other tissues such as the salivary gland and
brain [51]. When sodium was loaded, the classical RAAS
was suppressed, but the brain RAAS was activated [52].
The classical RAAS regulates sodium balance via a negative
feedback, but the brain RAAS forms a positive feedback cycle
to retain more sodium via increased renal SNSA. In the CNS,
sodium loading upregulates the messenger RNA for renin,
ACE, and angiotensin II AT-1 receptor [53]. Therefore, ICV
administration of Ang II augmented pressor responses in
sodium-loaded rats. Furthermore, aldosterone is present in
thebrain,anditslevelincreaseswithsodiumloading,leading
to increased SNSA [54]. The hypotensive eﬀects of MRB
are greater in the low-renin essential hypertensive patients
than in the normal renin hypertensives [55], which may be
explained by the activated RAAS in the brain. Since Ang
II administered into the CNS increases the BP along with
increasing the SNSA [56], augmented RAAS in the brain4 International Journal of Hypertension
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Figure 1: The classical RAAS (renal-renin and adrenal aldosterone system) regulates sodium balance via a negative feedback, but the brain
RAAS forms a positive feedback cycle to retain more sodium via increased renal SNSA.
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Figure 2: The most important component of the positive feedback
cycle may be the renal nerve because renal nerve ablation lowers
bloodpressureeveninhumans,andinhibitorsofRAASlowerblood
pressure even in low-renin essential hypertensives.
induced by sodium loading may be a probable cause of
essential hypertension. ICV injections of hypertonic saline
cause elevation of both BP and plasma DLI, which can be
blocked by ICV pretreatment with ARB [57]. Therefore,
increased brain RAAS by sodium has been suggested to be
involvedinhypertensiveactionsofsodium.Thereby,abdom-
inal SNSA, an upstream event of renal nerve stimulation,
is markedly increased, as conﬁrmed by the decreased renal
blood ﬂow observed using radioactive microspheres that
indicate activated renal SNSA [58]. Increased renal SNSA
decreases renal excretion of sodium by decreasing renal
bloodﬂowandincreasingrenaltubularsodiumreabsorption
[59]. Thus, increased intracranial sodium concentration
forms a positive circuit to retain sodium in the body
(Figure 2).
6.EpithelialSodiumChannelsMay Be aSensor
for SodiumConcentration
The mechanism underlying SNSA activation by sodium
intake cannot be explained by osmotic stimuli, since osmotic
stimulation by urea does not increase the BP [60]. Epithelial
sodium channels (ENaC) were thought to act as sensors for
sodium in the brain because these channels sense sodium on
the tongue [61]. This was proven because the ENaC-speciﬁc
inhibitor, benzamil, abolished the pressor responses to ICV
injections of hypertonic saline in a dose-dependent manner
[61]. Wang et al. [62] explored the connection of ENaC
with brain ouabain. They found that ICV administration of
hypertonic NaCl with a small dose of aldosterone caused
pressor responses accompanied by increased SNSA. This
response could be abolished by ICV pretreatment with
benzamil. Further, ICV pretreatment with Digibind, an
inhibitor of ouabain and digoxin, blocked the pressor eﬀects.
These ﬁndings indicate that ENaC is a sensor of sodium in
the brain, and its downstream eﬀects consist of aldosterone
and ouabain/digoxin release, causing an elevation in BP.
7.Relationship betweenRAASand Digitalisin
the Brain (Table 1)
Asmentionedabove,ICVpretreatmentwithARBcaninhibit
the pressor responses and DLI release into circulation caused
by ICV injections of hypertonic saline in rats. SodiumInternational Journal of Hypertension 5
Table 1: Intracranial pretreatments with one of these agents
blunt pressor responses caused by centrally administered sodium,
sodium-induced hypertension in Dahl salt-sensitive rats, hyper-
tension caused by subcutaneously injected angiotensin II, or
aldosterone.
(i) AT-1 receptor blocker
(ii) Mineralocorticoid receptor blocker
(iii) Aldosterone synthase inhibitor
(iv) Epithelial sodium channel (ENaC) blocker
(v) Antidigitalis blocking antibody
(vi) Anti-oxidative agent
loading upregulates RAS in the brain. ICV pretreatment
with spironolactone, an MRB, blocks both BP rises and
increased OLI in the hypothalamus and pituitary caused
by ICV administration of hypertonic NaCl [63], which
indicates that sodium loading increases aldosterone in the
brain [54]. In fact, aldosterone-like immunoreactivity in
the hypothalamus is increased in rats after sodium loading.
Since ICV pretreatment with spironolactone decreases the
intrahypothalamic content of OLI, ouabain may be located
downstream of aldosterone release. We recently found that
aldosterone caused a dose-dependent release of OLI from
cultured N1 cells of PVN origin [49].
8. The Central Effects of Ang II or Aldosterone
of Peripheral Origin
It has long been known that pressor responses occur due
to increased peripheral SNSA after Ang II is administered
via vertebral artery [64]. ICV administration of Ang II leads
to similar pressor responses [56]. Therefore, Ang II directly
acts on the CNS. Because pressor responses can be blocked
by ICV pretreatment with ARB, the eﬀect is mediated via
AT-1 receptors of Ang II [65]. For example, this response is
attenuated in subfornical organ-lesioned rats, which means
that one of the regions where Ang II acts is the subfornical
organ [65]. SC injection of low-dose Ang II for several days
leads to gradual increase in BP in approximately 3 days
[10]. ICV pretreatment with an inhibitor of aldosterone
synthase abolished the pressor response: it reduced the BP
elevation induced by a rather high SC dose of Ang II by
approximately 80%. Similar blocking eﬀects can be obtained
byeplerenone,anMRB,aswellasDigibind.Asimilarﬁnding
has been reported by other researchers [11] who showed that
RU28318, an MRB, abolishes the pressor responses caused
by SC injection of Ang II. These ﬁndings are in absolute
contrast to the classical interpretation that Ang II causes
hypertension by constricting the arterial beds and increasing
cardiac contraction. That MRBs are eﬀective in blocking
the central actions of Ang II indicates that Ang II produces
aldosterone in the brain. Speciﬁcally, the RAAS may be
playing a role in the brain similar to its role in the peripheral
system [66].
SC injections of aldosterone in addition to 1% saline
as drinking water gradually increased the BP by about
30mmHg; this is similar to the results for Ang II admin-
istration [11]. Water intake is concomitantly increased
as BP rises. Thereby, ICV administration of irbesartan,
an ARB, RU28318, or spironolactone almost completely
blocked the pressor responses and water intake. The pressor
response can also be suppressed by ICV pretreatments with
either apocynin (an NADPH oxidase inhibitor) or tempol
(a reactive oxygen species scavenger); this indicates that
the response is mediated by oxidative stress caused by
aldosterone in the brain. However, water intake was not
suppressed by suppression of oxidative stress, suggesting that
the pressor mechanism is independent from the 1% saline
intake response.
Because ICV pretreatment with MRB abolishes pressor
responses to systemic administration of aldosterone, it
follows that aldosterone of adrenocortical origin can act at
a central site to increase the BP. Like the interpretation for
AngII,conclusionofthisuniqueevidenceisentirelydiﬀerent
from the classical interpretation that aldosterone causes
hypertension by acting at the renal tubule to increase sodium
reabsorption. The novel ﬁndings that both Ang II and
aldosterone primarily act in the CNS to cause hypertension
are epoch-making discoveries that radically challenge the
classical interpretation (Figure 3).
9. Supposed Common CentralMechanism of
a Variety of Models of Hypertension
A hypertensive state means that the set point of the
baroreceptor reﬂex has shifted to a higher level, and the
sensitivity is decreased. Thus, when Ang II production is
blocked with ACEI, the set point is lowered to the normal
level and the sensitivity recovers [67]. It follows, therefore,
that Ang II is critically involved in the pathogenesis of
hypertension. The lowering of set point is not secondary to
normalizing the BP since the set point is still at the lower BP
level after treatment with ACEI, even when the BP has been
elevated to the hypertensive level with intravenous infusions
of phenylephrine. These ﬁndings indicate that inhibition of
RAAS completely normalizes BP regulation. The previously
mentioned evidence indicates that the involved RAAS is
not only of peripheral origin, but also of central origin.
However, since the vasomotor center exists in the CNS but
not in the periphery, Ang II or AT-1 receptors in the brain
will be primarily involved in changing the set point of the
baroreceptor reﬂex mechanism.
The epidemiological and experimental evidence previ-
ously discussed suggests that a human being who lived in
an environment with minimum intake of sodium during
long periods of Stone Age acquired a rigid mechanism to
retain sodium; this mechanism primarily consists of RAAS
a n dS N S A .M e a n w h i l e ,ah i g hB Pw o u l db ead e s i r a b l e
feature for living in low-salt conditions because people
with a high BP could be aroused more rapidly and ﬁght
more vigorously than those with lower BP. Atherosclerosis
was not a problem, as these people did not live long.
However, signiﬁcant changes in the sodium environment
occurred during a short period, and BP ﬂuctuation required6 International Journal of Hypertension
Table 2: Sodium retention can be achieved by a variety of causes.
(i) Excess intake of sodium; essential hypertension
(ii) Impaired renal excretion
(a) Renal insuﬃciency and renal failure
(b) Insulin resistance accompanied by obesity and/or the early stage of type II diabetes mellitus
(c) Increased aldosterone production; primary aldosteronism, idiopathic hyperaldosteronism, renovascular hypertension,
pheochromocytoma
(d) Other mineralocorticoid excess; 17a-hydroxylase deﬁciency, 11b-hydroxylase deﬁciency, apparent mineralocorticoid
excess syndrome and deoxycorticosterone-producing tumor
(e) Exaggerated renal sodium reabsorption; Liddle syndrome
Table 3: A list of secondary hypertension, supposedly caused by direct central actions of angiotensin II or mineralocorticoid.
Angiotensin II
Renovascular hypertension, aortic coarctation, renin-producing tumor, and pheochromocytoma
Mineralocorticoids
Aldosterone; primary aldosteronism, idiopathic hyperaldosteronism, renovascular hypertension, and pheochromocytoma
Other mineralocorticoids; 17a-hydroxylase deﬁciency, 11b-hydroxylase deﬁciency, apparent mineralocorticoid excess syndrome,
and deoxycorticosterone-producing tumor
correction; thus, the renal-renin and adrenal aldosterone
systems were equipped to form negative feedback. On the
other hand, brain RAAS may have been forming a positive
feedback system to retain sodium and maintain the BP at a
high level. Speciﬁcally, when sodium was loaded, opposing
mechanisms may be operational at the periphery and the
CNS. Therefore, human beings having a predisposition to
hypertensioncaneasilyelevatetheBPwithincreasedsodium
environment, which would result in sodium-sensitive essen-
tial hypertension. Similar mechanisms might be playing
a role in renal hypertension, obesity-related hypertension,
and senile hypertension with reduced renal function. In
renovascular hypertension, increased production of Ang II
and aldosterone might be directly acting at the central site
to cause hypertension. Similarly, in primary aldosteronism
and pseudoaldosteronism, MR in the CNS might be mainly
involved in the genesis of hypertension. Circumventricular
organs surrounding the third ventricle such as SFO, OVLT,
and area postrema are outside of the blood-brain barrier,
are anatomically diﬀerent from other brain tissues, and
show dense distribution of AT-1 receptors. These areas are
thought to sense information from systemic circulation.
For instance, when the SFO was electrically destroyed,
hypertension caused by chronic SC infusion of Ang II was
suppressed [65], indicating that Ang II acts at the SFO.
Further, hypotensive eﬀects of losartan, an ARB, are reduced,
which means that ARB is actually acting at the SFO to reduce
BP. Therefore, Ang II and aldosterone produced in the blood
may be acting at these central sites to elicit sympathetic
hyperactivity (Tables 2 and 3).
Thus, the central mechanism might be involved in every
type of hypertension.
10. Relationship between the Central
Vasopressor Mechanismand
AntihypertensiveAgents (Figure4)
As mentioned previously, the central cascade causing hyper-
tension may consist of Na+, ENaC, RAAS, digitalis, oxidative
stress, and SNSA. Therefore, agents acting at one of these
components will be excellent antihypertensive agents. In
fact, many antihypertensive agents have been identiﬁed
during the long history of screening for treatment of
hypertension, and the currently available antihypertensive
agents seem to be acting at any one of the components of
this cascade. For example, the role of diuretics is easy to
understand, because they reduce sodium loading. Although
ENaC inhibitors such as amiloride and triamterene are
known to reduce BP [68], these are not used as ﬁrst-
line antihypertensive agents primarily because of their low
receptor selectivity. Presently, blockers of RAAS such as
ACEIs, ARBs, direct renin inhibitors (DRIs), and MRBs are
the most frequently used agents. These may be acting at the
core of the mechanism causing hypertension, and therefore,
are the most reliable agents. Canrenone and rostaﬂoxin
(PST2238) are digitalis antagonists, which also reduce BP
[69, 70]. However, there remain some concerns particularly
in their potency and receptor selectivity. Antioxidants may
be eﬀective antihypertensive agents, since tempol is known
to reduce BP in hypertensive rats [71]. Centrally acting
sympatholytic agents such as α2-adrenoceptor agonists or
imidazoline receptor agonists are well known to reduce the
BP [72], but adverse eﬀects such as drowsiness and dry
mouth limit their usage. α1-Adrenoceptor antagonists are
also used for the treatment of hypertension [73]a n da r eInternational Journal of Hypertension 7
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Figure 3: Supposed common central mechanism of a variety of models of hypertension. The dotted line indicates the possible actions of
aldosterone on the RAS activation in the brain.
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patients with these agents, reﬂex tachycardia is missing. This means that these antihypertensive agents are resetting the blood pressure
regulatory center to a lower level besides their original actions such as vasodilation and diuresis.
known to act at the CNS level to decrease SNSA in rats [74].
CCBs are widely used in the clinical setting and are known
to cause sympathetic inhibition at the CNS in rats [75].
Although short-acting and potent CCBs cause sympathetic
activation by the baroreceptor reﬂex, gradual decreases in
BP with slow-acting agents do not cause reﬂex tachycardia
[76]. The fact that reﬂex tachycardia is not caused by the
agents listed before indicates that at least the ﬁrst and second
lines of antihypertensive agents are actually acting at a CNS
site to regulate BP and shifting the set point to a lower
level.
In general, the blood-brain barrier blocks the entry of
agents into the brain tissue. Therefore, concentrations of
systemically administered agents, except the lipid-soluble
agents, in the brain are very low. Therefore, it is believed that
antihypertensiveagents,exceptforα2-adrenoceptoragonists,
do not aﬀect the brain function. However, as mentioned
earlier,theseagentsactatthecircumventricularorganswhere
the barrier is lacking.
Currently available antihypertensive agents have been
screened for many years and can reduce the BP comfortably
without stimulating the heart and ﬁnally improve our8 International Journal of Hypertension
prognosis. This may be because these agents are acting at
the core mechanism of hypertension. In other words, the
common site of actions of these agents is the cause of hyper-
tension. Thus, it may be desirable to target development of
novel agents with selective action at the central mechanism
regulating BP in future studies.
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